# Obesity Reprogrammes Adipose Extracellular Vesicles to Induce Muscle Atrophy via miR‐150‐5p‐Mediated Transcriptional Silencing

**Authors:** Joshua M. J. Price, Michael Macleod, Thomas Nicholson, Caitlin M. Ditchfield, Bethy Airstone, Natalie Lachlan‐Jiraskova, Edward T. Davis, Kostas Tsintzas, Simon W. Jones

PMC · DOI: 10.1002/jcsm.70204 · Journal of Cachexia, Sarcopenia and Muscle · 2026-02-03

## TL;DR

Obesity-related fat tissue sends tiny vesicles that shrink muscle cells in older people, and this effect is partly due to a specific microRNA.

## Contribution

Identifies miR-150-5p in extracellular vesicles from obese fat tissue as a driver of age-dependent muscle atrophy.

## Key findings

- Non-lean EVs reduced myotube thickness in older adults but not in younger ones.
- miR-150-5p inhibition partially reversed muscle atrophy and reduced MAFbx expression.
- Non-lean EVs caused transcriptional changes linked to inflammation and mitochondrial dysfunction.

## Abstract

Sarcopenic obesity, where excess body fat coexists with reduced muscle mass and function, is becoming increasingly common in ageing populations and contributes to poor physical and metabolic health. Although adipose tissue–secreted factors are implicated in muscle decline, the specific mechanisms remain unclear. Extracellular vesicles (EVs), which carry regulatory cargo such as microRNAs (miRNAs) between cells, may play a key role in this adipose–muscle communication.

EVs were isolated from adipose‐conditioned media (ACM) collected from lean and non‐lean human donors using ultracentrifugation. Donors were grouped by BMI (lean: 20.7–24.4; non‐lean: 25.3–39.3) and age (younger: 31–56 years; older: 60–84 years). EVs were characterised using nanoparticle tracking analysis (NTA), ExoView, nanoscale flow cytometry (CytoFLEX Nano) and transmission electron microscopy (TEM). Primary human myoblasts were differentiated into myotubes and treated for 24 h with lean or non‐lean EVs (1.3 × 109 particles/mL) or left untreated. Myotube thickness was measured by immunofluorescence microscopy. Transcriptomic changes were assessed by bulk RNA sequencing. EV miRNA cargo was profiled by small RNA‐seq and validated by qPCR. The role of miR‐150‐5p was tested using antagomir inhibition.

Non‐lean EVs significantly reduced myotube thickness in older adult‐derived myotubes compared to both untreated controls (8.7 ± 1.66 μm vs. 12.4 ± 1.72 μm, p < 0.01) and lean EV‐treated myotubes (8.7 ± 1.66 μm vs. 13.2 ± 3.84 μm, p < 0.05), indicating a donor BMI‐specific effect. This atrophy was restricted to myotubes derived from older donors. The same experimental approach was applied to younger adult‐derived myotubes; no reduction in myotube thickness was observed.

MAFbx expression was significantly increased in response to non‐lean EVs (p < 0.05). RNA‐seq revealed 471 differentially expressed genes (DEGs) in EV‐treated versus untreated cells and 293 DEGs between lean and non‐lean EV conditions, with enrichment in inflammatory (TNF and IL1B), oxidative stress, mitochondrial and chromatin pathways. Small RNA‐seq identified seven differentially expressed miRNAs (annotated using miRBase release 22.1), including miR‐150‐5p and miR‐193b‐5p, both significantly upregulated in non‐lean EVs and validated by qPCR. Inhibiting miR‐150‐5p partially rescued myotube thickness (10.5 ± 1.37 μm vs. 8.7 ± 1.66 μm, p < 0.05) and reduced MAFbx expression.

EVs from non‐lean adipose tissue drive muscle atrophy and transcriptional changes in an age‐dependent manner. These effects are partially mediated by miR‐150‐5p, highlighting a mechanistic role for EV cargo in adipose‐muscle signalling. Targeting EV‐derived miRNAs may offer a novel strategy to combat muscle loss in obesity and ageing.

## Linked entities

- **Genes:** FBXO32 (F-box protein 32) [NCBI Gene 114907]
- **Diseases:** obesity (MONDO:0011122)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, LGR5 (leucine rich repeat containing G protein-coupled receptor 5) [NCBI Gene 8549] {aka FEX, GPR49, GPR67, GRP49, HG38}, Cd63 (CD63 antigen) [NCBI Gene 12512] {aka ME491, Tspan30}, Cebpb (CCAAT/enhancer binding protein beta) [NCBI Gene 12608] {aka C/EBPbeta, CRP2, IL-6DBP, LAP, LIP, NF-IL6}, Itga2b (integrin alpha 2b) [NCBI Gene 16399] {aka CD41, CD41B, GpIIb, alphaIIb}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, Pdk1 (pyruvate dehydrogenase kinase, isoenzyme 1) [NCBI Gene 228026] {aka B830012B01, D530020C15Rik}, Fbxo32 (F-box protein 32) [NCBI Gene 67731] {aka 4833442G10Rik, ATROGIN1, Gm20361, MAFbx}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Mir155 (microRNA 155) [NCBI Gene 387173] {aka Mirn155, mir-155, mmu-mir-155}, NR4A3 (nuclear receptor subfamily 4 group A member 3) [NCBI Gene 8013] {aka CHN, CSMF, MINOR, NOR1}, DES (desmin) [NCBI Gene 1674] {aka CDCD3, CSM1, CSM2, LGMD1D, LGMD1E, LGMD2R}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, Socs1 (suppressor of cytokine signaling 1) [NCBI Gene 12703] {aka Cish1, Cish7, JAB, SOCS-1, SSI-1}, FBXO32 (F-box protein 32) [NCBI Gene 114907] {aka Fbx32, MAFbx}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Cd9 (CD9 antigen) [NCBI Gene 12527] {aka Tspan29}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, TREM1 (triggering receptor expressed on myeloid cells 1) [NCBI Gene 54210] {aka CD354, TREM-1}, GPR166P (G protein-coupled receptor 166, pseudogene) [NCBI Gene 442206] {aka GPCR, PGR9}, TRIM63 (tripartite motif containing 63) [NCBI Gene 84676] {aka CMH31, IRF, MURF1, MURF2, RNF28, SMRZ}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Cd81 (CD81 antigen) [NCBI Gene 12520] {aka Tapa-1, Tapa1, Tspan28}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, MIR193B (microRNA 193b) [NCBI Gene 574455] {aka MIRN193B, mir-193b}
- **Diseases:** mitochondrial impairment (MESH:D028361), Obesity (MESH:D009765), loss of skeletal muscle mass and function (MESH:C536030), atrophic (MESH:D020966), Sarcopenia (MESH:D055948), Type 2 diabetes (MESH:D003924), Cachexia (MESH:D002100), Muscle Atrophy (MESH:D009133), muscle decline (MESH:D009135), Atrophy (MESH:D001284), glucose intolerance (MESH:D018149), muscle (MESH:D019042), insulin resistance (MESH:D007333), metabolic dysregulation (MESH:D021081), overweight (MESH:D050177), chronic liver disease (MESH:D008107), chronic kidney disease (MESH:D051436), ACM (MESH:D018205), Arthritis (MESH:D001168), metabolic disease (MESH:D008659), inflammation (MESH:D007249)
- **Chemicals:** fatty acid (MESH:D005227), TRIzol (MESH:C411644), lipid (MESH:D008055), tryptophan (MESH:D014364), methanol (MESH:D000432), DAPI (MESH:C007293), glucose (MESH:D005947), 3' cholesterol (-), (para)formaldehyde (MESH:C003043), SB203580 (MESH:C093642), DPBS (MESH:C012939), FITC (MESH:D016650), reactive oxygen species (MESH:D017382), CO2 (MESH:D002245), MTT (MESH:C070243), phospholipid (MESH:D010743), PBS (MESH:D007854), cholesterol (MESH:D002784), ruxolitinib (MESH:C540383)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** 293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12866798/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12866798/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12866798/full.md

---
Source: https://tomesphere.com/paper/PMC12866798